Efficacy and safety of low-dose prophylaxis of highly purified plasma-derived factor VIII concentrate produced by the National Blood Centre, Thai Red Cross Society

Haemophilia. 2018 Sep;24(5):e387-e390. doi: 10.1111/hae.13601. Epub 2018 Aug 17.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Blood Proteins / metabolism
  • Blood Proteins / therapeutic use*
  • Drug Dosage Calculations
  • Factor VIII / metabolism
  • Factor VIII / pharmacokinetics
  • Factor VIII / therapeutic use*
  • Female
  • Follow-Up Studies
  • Half-Life
  • Hemophilia A / complications
  • Hemophilia A / drug therapy*
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control*
  • Hemostatics / pharmacokinetics
  • Hemostatics / therapeutic use*
  • Humans
  • Male
  • Quality Control
  • Red Cross
  • Standard of Care
  • Thailand
  • Young Adult

Substances

  • Blood Proteins
  • Hemostatics
  • Factor VIII